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Introduction
Tissue-type plasminogen activator (t-PA) is a serine protease composed of 527 amino acids, containing five structural domains (the finger domain, the EGF domain, the kringle 1 domain, the kringle 2 domain and the serine protease domain) and three sugar chains at amino acid positions 117, 184 and 448. Because of its potent thrombolytic activity, wild-type t-PA has been widely used as a therapeutic thrombolytic agent for myocardial infarction (Llevadot et al., 2001; Collen et al., 2004) , and has recently been approved for the treatment of stroke. However, even in such emergent clinical care situations, t-PA must be administered by intravenous infusion because of its short half-life of 3-4 min. Consequently, several types of recombinant t-PA proteins have been developed to prolong the plasma retention time and thereby make a rapid bolus administration of t-PA possible.
Lanoteplase is one of the mutant forms of t-PA, which was developed with the recombinant DNA technology to achieve such an aim. Lanoteplase was produced by removing the EGF domain, a part of the finger domain, and by substituting Gln for the Asn residue at position 117 resulting in a removal of the sugar chain. Despite such a major structural modification, lanoteplase still exhibited a potent thrombolytic activity at much lower dose than t-PA both in vivo and in a rabbit model of jugular vein thrombosis (Furuya et al., 1999) . In addition, the efficiency of uptake by the liver of This article has not been copyedited and formatted. The final version may differ from this version. -6 -lanoteplase was much lower than that of t-PA, resulting in its longer plasma half-life and lower systemic clearance than those of t-PA (Hata et al., 1997a , Hata et al., 1997b , Larsen et al., 1989 . The lower plasma clearance of lanoteplase, compared with t-PA, has also been confirmed in patients with acute myocardial infarction (Kostis et al., 2002) . Thus, lanoteplase is expected to become a therapeutic thrombolytic agent, although its pharmacokinetic properties still remain uncertain.
Meanwhile, the clearance via receptor-mediated endocytosis (RME), in which protein ligands are internalized via receptors on the cell surface, subsequently lysosomal degradation is induced, has been recognized as an important mechanism for the systemic elimination of many bioactive proteins, including certain types of cytokines (Sugiyama et al., 1989; Liu et al., 1992; Kuwabara et al., 1996; Tang et al., 2004) . In fact, numerous studies have suggested that the low-density lipoprotein receptor-related protein (LRP) receptor, the asialoglycoprotein (ASGP) receptor and the mannose receptor presented on the liver cell-surface might play important roles as clearance mechanisms for t-PA (Camani et al., 1994) . Furthermore, Bu et al have suggested that the plasma proteins such as the plasminogen activator inhibitor (PAI)-1 are also associated with such receptor binding (Bu et al., 1992; Otter et al., 1992; Camani et al., 1994) . While pharmacokinetic analyses have been performed for various types of recombinant mutant t-PAs, only the plasma elimination profiles have been investigated
in most of those studies (Kuiper at al., 1995; Kuiper at al., 1996; Aoki et al., 2000; Aoki et al., 2001) . It is noteworthy that Oikawa et al (2000a Oikawa et al ( , 2000b attempted to characterize the kinetics of RME in the hepatocytes for pamiteplase, one of the mutant t-PAs, but the elimination mechanism of pamiteplase still remains unclear. The plasma level of t-PA mutants would be expected to be governed by the balance between the administration rate and the elimination efficiency. Therefore, it would be important to elucidate the elimination mechanism of these mutant proteins to clearly understand their pharmacology in vivo.
In the present study, we attempted to kinetically characterize the hepatic elimination mechanism of lanoteplase as compare with that of t-PA to elucidate the differences in the elimination pathways between two proteins. First, we performed integration plot analyses to assess their hepatic influx process in rats in vivo. Second, we characterized the RMEs of two proteins in primary cultures of rat hepatocytes.
Finally, we conducted the inhibition studies about the hepatic uptake, and pharmacokinetic analysis in gene-knockout mice to analyze the hepatic uptake mechanism of those proteins.
This article has not been copyedited and formatted. The final version may differ from this version. Radiolabeling. Lanoteplase and t-PA were radiolabeled with 125 I-sodium iodide by the peroxidase method (Miyachi et al., 1972) . Briefly, lanoteplase or t-PA dissolved in a buffer containing 50 mM citric acid, 50 mM creatinine, 50 mM histidine and 0.1%
Tween 80 (pH4.6) was first loaded on to a Sephadex G50 column (Amersham Biosciences, Sweden), followed by the addition of 125 I-sodium iodide (24 MBq) dissolved in a buffer containing 0.5 M Arginine, 0.4 M sodium acetate (pH 5.6) and 0.3 µg/mL lactoperoxidase (Carbiochem, Darmstadt, Germany). Then, after the addition of 0.02% H 2 O 2 , the column was incubated at 30 o C for 5 min, and the 125 I-lanoteplase or
Animals. Six-week-old male Sprague Dawley rats (190-240 g ) and six-week-old male C57BL/6N Crj mice (16 -20 g) were purchased from Charles River Japan Inc.
(Tsukuba, Japan). In addition, six-to eight-week-old male lrpap1 (-/-) mice (13-14 g)
were purchased from Jackson Laboratory (Bar Harbor, Maine).
Tissue distribution studies in vivo.

125
I-lanoteplase and 125 I-t-PA (1 µg/kg (0.37
MBq/kg)) with or without unlabeled ligand (100 µg/kg) were dissolved in a solution for injection (50 mM citric acid, 50 mM creatinine, 50 mM histidine and 0.1% Tween 80; pH 7.6) and injected via the femoral vein into rats under light pentobarbital (Dainippon Pharmaceuticals Co. LTD., Japan) anesthesia (40 mg/kg i.p.). Blood samples were then collected from the femoral artery at designated times for 10 min. Meanwhile, biopsy samples of the liver (approximately 100 mg) were obtained at 1.5, 3, 5 and 7 min after the injection. At 10 min after the i.v. administration, the rats were sacrificed, and the liver, kidney, heart, spleen and brain were immediately removed, weighed and the radioactivity counts were conducted with a gamma counter (COBRAII, Packard). 
The mice were sacrificed, and the liver, kidney, heart, lung, spleen and brain were immediately removed, weighed and radioactivity counts were performed.
Plasma samples were obtained by the addition of 3.8% sodium citrate to the blood specimens from the animals (1:9 vol/vol) and subsequent centrifugation at 8,000 g for Kinetic analysis for calculation of the total body clearance (CL tot ) and tissue uptake clearance (CL uptake ). The plasma concentration (Cp)-time profiles were fitted to a bi-exponential equation with a nonlinear least-squares method using the MULTI program (Yamaoka et al, 1981) . CL tot was calculated as the dose divided by the area under the plasma concentration-time curve (AUC) for an infinite time.
In regard to the hepatic distribution, the initial slope in a plot (designated as an integration plot) of the tissue:plasma concentration ratio (Kp) vs. the AUC/Cp yielded the CL uptake, where AUC was calculated by the use of the trapezoidal rule with extrapolation to the final sampling (Liu et al., 1992) . For tissues other than the liver, the Kp at time zero (Kp (0) ) was assumed to be the same as that in the extracellular space, was terminated by aspiration of the medium at designated times. The monolayer was then washed twice with the ice-cold standard medium, and the washed medium was mixed with the reaction medium aspirated as mentioned above. An aliquot (1 mL) of the mixture was then subjected to the TCA-precipitation technique, and TCA-precipitable (intact) and soluble (degradated) radioactivities were counted (Hata et al., 1997b) . In our previous analysis comparing the TCA-precipitation method with gel-filtration, polypeptide with molecular weight of higher than 15 kD was regarded as TCA-precipitable radioactivity (Hata et al., 1997b) . In our preliminary study, both 125 I-lanoteplase and 125 I-t-PA were incubated with rat liver homogenate which contains endogenous Type I deiodinase, and time-dependent increases in the TCA-soluble fraction were similar between the two proteins, suggesting that the rate of deionidation of the two proteins is the same. Accordingly, the monolayer was incubated for 20 min 
Kinetic analysis for receptor-mediated endocytosis.
Regarding the receptor binding on cell-surface, internalization and degradation of the ligand, the following three equations can represent the mass balance in each process:
where X s , X int and X deg are the amounts of surface-bound, internalized and degraded ligand, respectively, at time t, whereas k on , k off , k int and k deg indicate the rate constants for association, dissociation, internalization and degradation, respectively. The L and R free are ligand concentration in medium and free (unoccupied) receptor on cell-surface.
At the earlier time period, the Eq. 2 can be simplified to:
The integration of Eq. 4 and Eq. 3 yields:
where AUC s and AUC int are area under the time course of X s and X int , respectively. Thus, initial slope in the plot of X int vs AUC s yields k int whereas that in the plot of X deg vs AUC int yields k deg . Since we used a tracer concentration of the ligand, the R free was assumed to be constant. In addition, L was also assumed to be constant, since the decrease in medium ligand concentration was found to be minimal in the present study.
Thus, the Eq. 1 can be simply integrated to be:
Therefore, the slope in sigma-minus plot for X s yields sum of k off and k int , and subtraction of k int from the slope yields k off .
Statistical Analysis. Statistical comparisons between the treatment group were performed using one-way analysis of variance (ANOVA). When ANOVA showed significant differences among the groups, multiple pairwise comparisons of each experimental group versus the control group were performed using Dunnett's test to identify which group differences accounted for the significant P values. The p-value This article has not been copyedited and formatted. The final version may differ from this version. 
I-t-PA in rats.
The plasma concentration-time profiles after i.v. administration of 1 and 100 µg/kg of 125 I-lanoteplase and 125 I-t-PA are shown in Fig. 1 . The disappearance of lanoteplase from the plasma was significantly slower than that of t-PA, with the plasma concentration of lanoteplase at 10 min after its administration being about 5-fold higher than that of the corresponding concentration of 125 I-t-PA (Fig. 1 ).
Since the liver has been considered to be the major clearance organ for t-PA (Camani et al., 1994) , the hepatic uptake profile of both lanoteplase and t-PA were examined by the integration plot analysis. The integration plot for the liver was almost linear up to 10 min for both proteins, although the slope for t-PA was much steeper than that for lanoteplase, after administration of either 1 or 100 µg/kg (Fig. 2) . The CL uptake s in the liver and other organs are shown in Fig. 3 . The CL uptake s of lanoteplase in the liver, spleen and heart were significantly lower than the corresponding values of t-PA, in particular, that of lanoteplase in the liver was just about 7% of t-PA's (Fig. 3A) .
Meanwhile, the CL uptake of lanoteplase in the kidney was about 1.6 times higher than that of t-PA (Fig. 3A) . In addition, the CL uptake of t-PA per kg body weight in the liver was the highest among all organs examined, whereas those of lanoteplase in the liver and kidney were comparable (Fig. 3B) . Furthermore, those of lanoteplase and t-PA in This article has not been copyedited and formatted. The final version may differ from this version. (Camani et al., 1994) . The difference in the CL tot between lanoteplase and t-PA was comparable to the difference in the CL uptake per kg body weight in the liver between the two proteins (Fig. 3B, 3C) . Thus, the improved stability in the systemic circulation of lanoteplase as compared with that of t-PA can be principally explained by the lower hepatic elimination of this protein, as hypothesized by us in our previous report (Hata et al., 1997b) . -19 - (Brock 1997; Crawford et al., 1999; Emeis et al, 1985) . The Kp of lanoteplase in the liver at 3 min after its administration was not affected by the co-administration of mannose, however, it decreased significantly by the co-administration of lactoferrin alone and by the co-administration of lactoferrin plus mannose (Fig. 5A) . On the other hand, mannose and/or lactoferrin co-administration decreased the Kp of t-PA in the liver (Fig. 5B) . The trend of Kp of lanoteplase in the kidney was similar to that in the liver (Fig. 5A, 5C ), whereas that of t-PA in the kidney was not significantly affected by the co-administration of neither mannose, lactoferrin, nor lactoferrin plus mannose (Fig.   5D ).
Kinetic analysis of RME
It has been suggested that the hepatic disposition of t-PA was at least partially mediated by the LDL receptor-related protein (LRP) (Bu et al, 1992) . The LRP-associated protein (LRPAP in humans, RAP in mice) may act as a folding chaperone for LRP (Willnow et al, 1996) and has been widely used as a specific inhibitor of LRP. Target mutation in the lrpap1 gene causes functional deficiency of LRP, with reduction in its expression levels in the liver and lrpap1 (-/-) mice are now commercially available. Therefore, in the present study, lrpap1 (-/-) mice were used to investigate the possible involvement of LRP in the hepatic disposition of lanoteplase.
While the Kp of lanoteplase in the liver tended to be decreased in the lrpap1 (-/-) mice (Fig. 5A) , an obvious decrease of the Kp of t-PA was observed in the liver of these mice This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
It has been obligatory to administer t-PA by intravenous infusion in emergency medical situations due to its short half-life (Collen et al., 1984; Verstraete et al., 1985) .
Lanoteplase is a brand new mutant t-PA produced as a result of a major structural modification with a molecular size 4/5 th that of t-PA. It has similarly potent thrombolytic activity as t-PA (Furuya et al., 1999 ) and pharmacokinetic properties that should enable bolus intravenous administration for the treatment of acute emergencies.
The present study indicated that the major clearance organ for both t-PA and lanoteplase is the liver (Fig. 3) . However, the hepatic CL uptake of lanoteplase was quite smaller than that of t-PA (Fig. 2, 3 ), and such smaller hepatic uptake could be a reason for the prolonged retention of lanoteplase in the circulating blood.
Previous reports have revealed that about 60% of hepatic distribution of t-PA was associated with parenchymal cells, and the remaining 40% was associated with non-parenchymal cells of the liver (Kuiper at al., 1988; Rijken et al., 1990) . The LRP and ASGP receptors on the parenchymal cells and also the mannose receptors on the non-parenchymal cells of the liver could represent the clearance receptors for t-PA on the liver cell-surface (Bu et al., 1992; Otter et al., 1992; Camani et al., 1994) . We therefore investigated the RME mechanism for lanoteplase and t-PA in primary cultured rat hepatocytes. The amounts of surface-bound, internalized and degradation products This article has not been copyedited and formatted. The final version may differ from this version. 
-22 -of lanoteplase were smaller than those of t-PA (Fig. 4B, 4C , and 4D), suggesting that lanoteplase also underwent RME in the parenchymal cells just like t-PA, but its clearance via RME was smaller than that of t-PA. Cell-surface binding of lanoteplase assessed at 4 o C was lower than that of t-PA (Fig. 4A) , suggesting lower receptor binding affinity of lanoteplase. Furthermore, the kinetic analyses suggested that a reduction in internalization and degradation (Table 1) could also be the reason for lower clearance efficiency of lanoteplase via RME.
It is considered important from a perspective of safety in the clinical use to clarify which ones among the three receptors in the liver cells are responsible for the elimination of lanoteplase. The CL uptake of lanoteplase in the liver was decreased only when co-administered with lactoferin or administered to lrpap1 (-/-) mice (Fig. 5A) , even though that of t-PA decreased when co-administered under the same experimental conditions including mannose (Fig. 5B) . These results suggested that the ASGP receptor and the specific receptor for LRPAP, presumably the LRP receptor, were responsible for the distribution of lanoteplase into the liver. Meanwhile, the LRP, the ASGP and the mannose receptors were responsible for the distribution of t-PA into the liver. Based on these results, it is considered that the binding of lanoteplase to the mannose receptor may have completely disappeared because of the removal of the mannose-rich sugar chain from its molecule at Asn 117. This is compatible with the This article has not been copyedited and formatted. The final version may differ from this version. -23 -previous report that the CL tot of another structural mutant of t-PA, in which Asn at 117 was substituted by Gln and a sugar chain was removed, was decreased by 38% of that of t-PA (Aoki et al. 2001) . LRP is known to consist of four clusters, and the t-PA･PAI-1 complex binds to cluster II of LRP (Neels et al., 1999) . The binding affinity of t-PA･ PAI-1 complex to the LRP receptor is ten times higher than that of non-protein binding (free) t-PA (Horn et al., 1997) . Moreover, it has been reported that lactoferrin binds to clusters II and IV of the LRP (Bennatt et al., 1997; McAbee et al., 1998) . Considering that the distribution of lanoteplase into the liver was inhibited by co-administration of lactoferrin (Fig. 5) , and that lanoteplase was a mutant of t-PA, it would appear that lanoteplase is also taken up by the liver mainly as a protein-bound complex. On the other hand, the ASGP receptor binds to t-PA and this receptor is known to recognize the structural carbohydrates of t-PA at Thr 61, Arg 184, and Asn 448 (Camani et al., 1998; Nagaoka et al., 2003) . As the carbohydrate at Asn 448 is also retained in lanoteplase, the drug appears to bind to the ASGP receptor.
It is noteworthy that the CL uptake per g tissue of lanoteplase in the kidney was greater than that in the liver, and that the CL uptake values per kg body weight of this compound in the liver and kidney were comparable (Fig. 3) . This result showed that the kidney may also be an important clearance organ for lanoteplase. Hepatic dysfunction may severely affect the pharmacokinetics when the clearance organ is only This article has not been copyedited and formatted. The final version may differ from this version. -24 -the liver, and multiple elimination pathways may be beneficial for the clearance of therapeutic agents. Therefore, further clinical studies are necessary to examine whether lanoteplase might be safer than the traditional t-PA when it is administered to the specific target population such as the patients with hepatic dysfunction, those receiving concomitant estradiol administration or older patients. Until now, there have been few reports about the renal elimination mechanism of t-PA even though it was suggested that t-PA might be taken up by one of the members of LDL receptor family in this organ (Camani et al., 1994) . Considering the significance of renal elimination (Fig. 3) , it would also be important for lanoteplase to clarify the mechanism of renal elimination in detail. The present study indicated the similar patterns in decrease of the Kp of lanoteplase between kidney and liver ( Fig. 5C ), implying that RME may also be involved in renal disposition, although the higher CL uptake of lanoteplase in the kidney (Fig. 3 ) may presumably be explained by the easier glomerular filtration of lanoteplase because of its smaller molecular size (50 kD) than that of t-PA (64 kD).
In our previous study using gel filtration chromatography, the major plasma proteins that bind to t-PA and lanoteplase were different; that is, the binding fractions for t-PA to PAI-1 and α 2-macroglobulin were 19 and 8%, whereas the corresponding values for lanoteplase were 6 and 14%, respectively (Hata et al., 1997b) . On the other hand, the uptake of t-PA into the liver has been reported to be affected by its binding to -25 -PAI-1 or α 2-macroglobulin, presumably because t-PA was taken up into the liver as a complex with these proteins (Camani et al., 1994 , Camani et al., 2000 . Thus, it is possible that the binding of lanoteplase to the plasma proteins or these receptors is changed because of conformational changes following the removal of several structural domains in t-PA. To conduct an in-depth analysis of the elimination mechanisms, furtherer examination using the protein complexes might be needed.
In conclusion, lanoteplase showed long blood retention mainly because of a decrease in the efficiency of RME in the liver. The primary receptors related to the hepatic uptake for lanoteplase seemed to be the LRP and the ASGP receptors and the contribution of mannose receptor appeared to be small. This article has not been copyedited and formatted. The final version may differ from this version. -37 - Tables   Table 1 Kinetic 
